GlassScriptPhysician profile
Charles R Kirkham
NPI 1316911191
$54,404.85
in general payments reported to CMS, 2019-2025
29 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,901 · 2020: $64.33 · 2021: $6,725 · 2022: $22K · 2023: $8,182 · 2024: $338 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Consulting Fee: $2,080 · Food and Beverage: $1,612 · Travel and Lodging: $1,183 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,917.00 |
| Consulting Fee | $2,080.00 |
| Food and Beverage | $1,612.43 |
| Travel and Lodging | $1,183.00 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $28,209.30 | 2021-2022 | |
| Biogen, INC. | $12,109.69 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $7,769.09 | 2023-2024 | Myfembree |
| Duchesnay USA Incorporated | $4,637.28 | 2019 | |
| Abbvie INC. | $321.77 | 2019-2023 | |
| Astellas Pharma US INC | $254.01 | 2023 | Veozah |
| Exeltis, USA INC. | $201.09 | 2019-2025 | Twirla, Slynd |
| Sage Therapeutics, LLC | $147.45 | 2024-2025 | Zurzuvae |
| Allergan, INC. | $126.35 | 2019 | |
| Mayne Pharma Commercial LLC | $123.77 | 2022-2024 | |
| Myriad Women'S Health, INC. | $83.73 | 2023 | Myrisk |
| Organon LLC | $70.06 | 2023-2025 | Nexplanon |
| Exact Sciences Corporation | $66.35 | 2023-2025 | Cologuard Collection Kit |
| Monaghan Medical Corporation | $53.79 | 2024 | Aeroeclipse |
| Northgate Technologies, INC. | $39.25 | 2024 | Stimsite |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $37.40 | 2019 | |
| Evofem Biosciences, INC. | $34.82 | 2021 | |
| Supernus Pharmaceuticals, INC. | $23.72 | 2025 | Qelbree |
| Boston Scientific Corporation | $21.29 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.95 | 2020 | |
| Hologic Sales and Service, LLC | $16.69 | 2021 | |
| Integra Lifesciences Corporation | $15.29 | 2023 | Medihoney, Biodrestore, Biofix |
| Coopersurgical, INC. | $12.51 | 2021 | |
| Aspira Women'S Health INC | $9.20 | 2024 | Ova1 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Kirkham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.